MultiCell Technologies, Inc.

Equities

MCET

US62544S2005

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:20:24 2024-04-16 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		0.00%	0.00%

2015	MultiCell Technologies, Inc. Auditor Raises 'Going Concern' Doubt	CI
2014	MultiCell Technologies Files Novel Antibody-Drug Conjugate Patent Application	CI

MultiCell Technologies, Inc. Auditor Raises 'Going Concern' Doubt

February 28, 2014 at 09:45 am EST

MultiCell Technologies, Inc. filed its 10-K on Feb 28, 2014 for the period ending Nov 30, 2013. In this report its auditor, Eide Bailly, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about MultiCell Technologies, Inc.

MultiCell Technologies, Inc. Auditor Raises 'Going Concern' Doubt	15-03-01	CI
MultiCell Technologies Files Novel Antibody-Drug Conjugate Patent Application	14-12-10	CI
MultiCell Technologies Inc. Files U.S. and International Patent Applications for the Treatment of Liver Cancer	14-03-20	CI
MultiCell Technologies, Inc. Auditor Raises 'Going Concern' Doubt	14-02-28	CI
MultiCell Technologies, Inc. Files U.S. Provisional Patent Application for its New Class of RNA Therapeutics	14-01-15	CI
MultiCell Technologies, Inc. Files U.S. Patent Application for Targeted Delivery of MCT-485	13-11-13	CI
MultiCell Technologies, Inc. and Genisphere, LLC Evaluate Targeted Delivery of MCT-485	13-08-06	CI
Multicell Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2013	13-07-24	CI
MultiCell Technologies, Inc. Auditor Raises 'Going Concern' Doubt	13-02-28	CI
Grant G. Miller Joins Board of MultiCell Technologies, Inc	12-10-22	CI
MultiCell Technologies, Inc. Adds Scott Lukeman to its Board of Directors	12-09-06	CI
MultiCell Technologies, Inc. Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in Vitro Models	12-08-10	CI
MultiCell Technologies, Inc. Auditor Raises 'Going Concern' Doubt	12-02-28	CI

Chart MultiCell Technologies, Inc.

Duration

Period

More charts

Company Profile

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company. The Company and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The Company's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MULTICELL TECHNOLOGIES, INC.	0.00%	5K
IQVIA HOLDINGS INC.	-1.42%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.97%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.82%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.55%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.07%	11.68B
MEDPACE HOLDINGS, INC.	+21.36%	11.6B
UNITED THERAPEUTICS CORPORATION	+8.20%	11.15B

Other Biotechnology & Medical Research